CDK11p58 inhibits ERα-positive breast cancer invasion by targeting integrin β3 via the repression of ERα signaling

BMC Cancer

Yayun Chi¹  Sheng Huang¹  Lei Wang¹  Ruoji Zhou¹  Lisha Wang¹  Xiuying Xiao¹  Dali Li¹  Ying Cai¹  Xiaoyan Zhou¹  Jiong Wu¹ 

[1] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

关键词: TaqMan assay;    Tissue array;    ERα;    Integrinβ3;    Metastasis;    CDK11^p58;   

Others  :  1125225
DOI  :  10.1186/1471-2407-14-577

 received in 2014-02-14, accepted in 2014-08-05,  发布年份 2014

【 摘 要 】

Background

CDK11^p58, a Ser/Thr kinase that belongs to the cell division cycle 2-like 1 (CDC2L1) subfamily, is associated with cell cycle progression, tumorigenesis and apoptotic signaling. CDK11^p58 is also involved in the regulation of steroid receptors, such as androgen and estrogen receptors. We previously found that CDK11^p58 was abnormally expressed in prostate cancer. However, its role in breast cancer remains unclear.

Methods

CDK11^p58 expression was evaluated by immunohistochemical staining in a tissue array. A Transwell assay was used to detect invasion and metastasis in breast cancer cells. The TaqMan® Metastasis Gene Expression Assay was used to search for potential downstream factors in the CDK11^p58 signaling pathway. qRT-PCR was used to evaluate mRNA levels, and the dual luciferase array was used to analyze promoter activity. Western blotting was used to detect the protein level.

Results

CDK11^p58 expression was negatively correlated with node status (P = 0.012), relapse status (P = 0.002) and metastasis status (P = 0.023). Kaplan-Meier survival curves indicated that the disease-free survival (DFS) was significantly poor in breast cancer patients with low CDK11 expression. Interestingly, using the breast cancer cell lines ZR-75-30 and MDA-MB-231, we found that CDK11^p58 was capable of repressing the migration and invasion of ERα-positive breast cancer cells, but not ERα-negative breast cancer cells, in a kinase-dependent manner. Gene expression assays demonstrated that integrin β3 mRNA was dramatically repressed by CDK11^p58, and luciferase results confirmed that the integrin β3 promoter was inhibited by CDK11^p58 through ERα repression. The expression of integrin β3 was highly related to ERα signaling; ERα overexpression stimulated integrin β3 expression, whereas siRNA-mediated knockdown of ERα attenuated integrin β3 expression.

Conclusions

These data indicate that CDK11^p58 is an anti-metastatic gene in ERα-positive breast cancer and that the regulation of integrin β3 by CDK11^p58 via the repression of ERα signaling may constitute part of a signaling pathway underlying breast cancer invasion.

【 授权许可】

   
2014 Chi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Snyder RD: New concepts in breast cancer therapy. Intern Med J 2004, 34(5):266-269.
• [2]Wang Y, Zhou BP: Epithelial-mesenchymal Transition-A Hallmark of Breast Cancer Metastasis. Cancer Hallm 2013, 1(1):38-49.
• [3]Almendro V, Kim HJ, Cheng YK, Gonen M, Itzkovitz S, Argani P, Van Oudenaarden A, Sukumar S, Michor F, Polyak K: Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 2014, 74(5):1338-1348.
• [4]Tsukamoto K, Ito N, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Nakamura Y, Emi M: Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma. Cancer 1998, 82(2):317-322.
• [5]Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S: Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 1999, 79(9–10):1468-1474.
• [6]Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY: Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 2006, 6:92.
• [7]Borg A, Zhang QX, Olsson H, Wenngren E: Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. Genes Chromosomes Cancer 1992, 5(4):311-320.
• [8]Lahti JM, Xiang J, Heath LS, Campana D, Kidd VJ: PITSLRE protein kinase activity is associated with apoptosis. Mol Cell Biol 1995, 15(1):1-11.
• [9]Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA: CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128(3):459-475.
• [10]Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin WG Jr: The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008, 22(7):884-893.
• [11]Climent J, Perez-Losada J, Quigley DA, Kim IJ, Delrosario R, Jen KY, Bosch A, Lluch A, Mao JH, Balmain A: Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J Clin Oncol 2010, 28(23):3770-3778.
• [12]Malumbres M, Harlow E, Hunt T, Hunter T, Lahti JM, Manning G, Morgan DO, Tsai LH, Wolgemuth DJ: Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009, 11(11):1275-1276.
• [13]Chi Y, Zhang C, Zong H, Hong Y, Kong X, Liu H, Zou W, Wang Y, Yun X, Gu J: Identification of CDK11p58 Thr-370 responsible for its autophosphorylation, dimerization and kinase activity. J Biol Chem 2010, 286(3):1748-1757.
• [14]Li Z, Wang H, Zong H, Sun Q, Kong X, Jiang J, Gu J: Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide. Biochem Biophys Res Commun 2005, 327(2):628-636.
• [15]Guo HQ, Gao M, Ma J, Xiao T, Zhao LL, Gao Y, Pan QJ: Analysis of the cellular centrosome in fine-needle aspirations of the breast. Breast Cancer Res 2007, 9(4):R48.
• [16]Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, Krause U, Ho AD, Bastert G, Kramer A: Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer 2003, 107(3):346-352.
• [17]Olson JE, Wang X, Pankratz VS, Fredericksen ZS, Vachon CM, Vierkant RA, Cerhan JR, Couch FJ: Centrosome-related genes, genetic variation, and risk of breast cancer. Breast Cancer Res Treat 2011, 125(1):221-228.
• [18]Petretti C, Savoian M, Montembault E, Glover DM, Prigent C, Giet R: The PITSLRE/CDK11p58 protein kinase promotes centrosome maturation and bipolar spindle formation. Embo Rep 2006, 7(4):418-424.
• [19]Franck N, Montembault E, Rome P, Pascal A, Cremet JY, Giet R: CDK11(p58) is required for centriole duplication and Plk4 recruitment to mitotic centrosomes. PLoS One 2011, 6(1):e14600.
• [20]Zong H, Chi Y, Wang Y, Yang Y, Zhang L, Chen H, Jiang J, Li Z, Hong Y, Wang H, Yun X, Gu J: Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol Cell Biol 2007, 27(20):7125-7142.
• [21]Chi Y, Hong Y, Zong H, Wang Y, Zou W, Yang J, Kong X, Yun X, Gu J: CDK11p58 represses vitamin D receptor-mediated transcriptional activation through promoting its ubiquitin-proteasome degradation. Biochem Biophys Res Commun 2009, 386(3):493-498.
• [22]Wang Y, Zong H, Chi Y, Hong Y, Yang Y, Zou W, Yun X, Gu J: Repression of estrogen receptor alpha by CDK11p58 through promoting its ubiquitin-proteasome degradation. J Biochem 2009, 145(3):331-343.
• [23]Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354(3):270-282.
• [24]Sanchez AM, Flamini MI, Baldacci C, Goglia L, Genazzani AR, Simoncini T: Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 2010, 24(11):2114-2125.
• [25]Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewski S, Strongin AY: Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res 2006, 66(5):2716-2724.
• [26]Chen C, Yan J, Sun Q, Yao L, Jian Y, Lu J, Gu J: Induction of apoptosis by p110C requires mitochondrial translocation of the proapoptotic BCL-2 family member BAD. Febs Lett 2006, 580(3):813-821.
• [27]Harper JW, Adams PD: Cyclin-dependent kinases. Chem Rev 2001, 101(8):2511-2526.
• [28]Trembley JH, Loyer P, Hu D, Li T, Grenet J, Lahti JM, Kidd VJ: Cyclin dependent kinase 11 in RNA transcription and splicing. Prog Nucleic Acid Res Mol Biol 2004, 77:263-288.
• [29]Jung HH, Park YH, Jun HJ, Kong J, Kim JH, Kim JA, Yun J, Sun JM, Won YW, Lee S, Kim ST, Ahn JS, Im YH: Matrix metalloproteinase-1 expression can be upregulated through mitogen-activated protein kinase pathway under the influence of human epidermal growth factor receptor 2 synergized with estrogen receptor. Mol Cancer Res 2010, 8(7):1037-1047.
• [30]Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, Nolan C, Coombes RC: Estrogen and progesterone receptors in the normal female breast. Cancer Res 1991, 51(7):1817-1822.
• [31]Giretti MS, Fu XD, De Rosa G, Sarotto I, Baldacci C, Garibaldi S, Mannella P, Biglia N, Sismondi P, Genazzani AR, Simoncini T: Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One 2008, 3(5):e2238.
• [32]Qi X, Tang J, Loesch M, Pohl N, Alkan S, Chen G: p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res 2006, 66(15):7540-7547.
• [33]Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Lubinski J: The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2010, 121(3):639-649.
• [34]Shaw LM: Integrin function in breast carcinoma progression. J Mammary Gland Biol Neoplasia 1999, 4(4):367-376.
• [35]Taddei I, Faraldo MM, Teuliere J, Deugnier MA, Thiery JP, Glukhova MA: Integrins in mammary gland development and differentiation of mammary epithelium. J Mammary Gland Biol Neoplasia 2003, 8(4):383-394.
• [36]Hood JD, Cheresh DA: Role of integrins in cell invasion and migration. Nat Rev Cancer 2002, 2(2):91-100.
• [37]Lei Y, Huang K, Gao C, Lau QC, Pan H, Xie K, Li J, Liu R, Zhang T, Xie N, Nai HS, Wu H, Dong Q, Zhao X, Nice EC, Huang C, Wei Y: Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells. Mol Cell Proteomics 2011, 10(10):M110-M5397.
• [38]Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, Shattil SJ, Cheresh DA: An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 2009, 15(10):1163-1169.
• [39]Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM: The nuclear receptor superfamily: the second decade. Cell 1995, 83(6):835-839.
• [40]Beato M, Herrlich P, Schutz G: Steroid hormone receptors: many actors in search of a plot. Cell 1995, 83(6):851-857.